Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Berg C, Spiess K, Lüttichau HR, Rosenkilde MM.

Pharmacol Res Perspect. 2016 Oct 18;4(6):e00262. doi: 10.1002/prp2.262. eCollection 2016 Oct 18.

2.

Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5.

Tam K, Schultz M, Reyes-Robles T, Vanwalscappel B, Horton J, Alonzo F 3rd, Wu B, Landau NR, Torres VJ.

MBio. 2016 Dec 13;7(6). pii: e02024-16. doi: 10.1128/mBio.02024-16.

3.

C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Barmania F, Pepper MS.

Appl Transl Genom. 2013 May 26;2:3-16. eCollection 2013 May 26. Review.

4.

Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5).

Karlshøj S, Amarandi RM, Larsen O, Daugvilaite V, Steen A, Brvar M, Pui A, Frimurer TM, Ulven T, Rosenkilde MM.

J Biol Chem. 2016 Dec 23;291(52):26860-26874. doi: 10.1074/jbc.M116.740183. Epub 2016 Nov 10.

PMID:
27834679
5.

Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation.

Liebick M, Schläger C, Oppermann M.

PLoS One. 2016 Jun 16;11(6):e0157502. doi: 10.1371/journal.pone.0157502. eCollection 2016 Jun 16.

6.

On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Vauquelin G, Van Liefde I, Swinney DC.

Br J Pharmacol. 2016 Apr;173(8):1268-85. doi: 10.1111/bph.13445. Epub 2016 Mar 15. Review.

PMID:
26808227
7.

Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations.

Salmas RE, Yurtsever M, Durdagi S.

Sci Rep. 2015 Aug 24;5:13180. doi: 10.1038/srep13180.

8.

P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.

Giroud C, Marin M, Hammonds J, Spearman P, Melikyan GB.

J Virol. 2015 Sep;89(18):9368-82. doi: 10.1128/JVI.01178-15. Epub 2015 Jul 1.

9.

Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.

Lau G, Labrecque J, Metz M, Vaz R, Fricker SP.

J Biol Chem. 2015 Apr 24;290(17):11041-51. doi: 10.1074/jbc.M115.640169. Epub 2015 Mar 12.

10.

Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Das D, Maeda K, Hayashi Y, Gavande N, Desai DV, Chang SB, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2015 Apr;59(4):1895-904. doi: 10.1128/AAC.04654-14. Epub 2015 Jan 12.

11.

Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor.

Abrol R, Trzaskowski B, Goddard WA 3rd, Nesterov A, Olave I, Irons C.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13040-5. doi: 10.1073/pnas.1413216111. Epub 2014 Aug 25.

12.

Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Thiele S, Mungalpara J, Steen A, Rosenkilde MM, Våbenø J.

Br J Pharmacol. 2014 Dec;171(23):5313-29. doi: 10.1111/bph.12842.

13.
14.

Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.

Tamamis P, Floudas CA.

PLoS One. 2014 Apr 24;9(4):e95767. doi: 10.1371/journal.pone.0095767. eCollection 2014 Apr 24.

15.

A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands.

Swinney DC, Beavis P, Chuang KT, Zheng Y, Lee I, Gee P, Deval J, Rotstein DM, Dioszegi M, Ravendran P, Zhang J, Sankuratri S, Kondru R, Vauquelin G.

Br J Pharmacol. 2014 Jul;171(14):3364-75. doi: 10.1111/bph.12683.

16.

The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators..

Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.

17.

Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).

Steen A, Sparre-Ulrich AH, Thiele S, Guo D, Frimurer TM, Rosenkilde MM.

Br J Pharmacol. 2014 Mar;171(6):1566-79. doi: 10.1111/bph.12553.

18.

Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.

Li BQ, Niu B, Chen L, Wei ZJ, Huang T, Jiang M, Lu J, Zheng MY, Kong XY, Cai YD.

PLoS One. 2013 Jun 6;8(6):e65207. doi: 10.1371/journal.pone.0065207. Print 2013.

19.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

20.

Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7.

Steen A, Thiele S, Guo D, Hansen LS, Frimurer TM, Rosenkilde MM.

J Biol Chem. 2013 May 3;288(18):12511-21. doi: 10.1074/jbc.M112.449587. Epub 2013 Mar 14.

Supplemental Content

Support Center